A Decade of Progress: GLP-1 Drugs and SGLT2 in Cardiovascular Diabetes Care
Review of a decade of progress in T2D cardiovascular management chronicles the transformative impact of GLP-1 drugs and SGLT2 inhibitors on heart outcomes.
Quick Facts
What This Study Found
Review of a decade of progress in T2D cardiovascular management chronicles the transformative impact of GLP-1 drugs and SGLT2 inhibitors on heart outcomes.
Key Numbers
Review covers the decade of CVOTs since 2015. Multiple trials with tens of thousands of patients demonstrating reduced MACE, CV death, and heart failure.
How They Did This
In publication.
Why This Research Matters
Relevant to peptide therapeutics.
The Bigger Picture
Advances peptide evidence.
What This Study Doesn't Tell Us
In publication.
Questions This Raises
- ?Long-term implications?
- ?Evidence comparison?
- ?Next steps?
Trust & Context
- Key Stat:
- Key finding Review of a decade of progress in T2D cardiovascular management chronicles the transformative impact
- Evidence Grade:
- Based on design.
- Study Age:
- Published in 2025.
- Original Title:
- A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.
- Published In:
- Frontiers in endocrinology, 16, 1605746 (2025)
- Authors:
- Aristizábal-Colorado, David, Corredor-Rengifo, David, Sierra-Castillo, Santiago, López-Corredor, Carolina, Vernaza-Trujillo, David-Alexander, Weir-Restrepo, Danilo, Izquierdo-Condoy, Juan S, Ortiz-Prado, Esteban, Rico-Fontalvo, Jorge, Gómez-Mesa, Juan-Esteban, Abreu-Lomba, Alin, Rivera-Martínez, Wilfredo-Antonio
- Database ID:
- RPEP-09977
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does this mean?
Review of a decade of progress in T2D cardiovascular management chronicles the transformative impact of GLP-1 drugs and SGLT2 inhibitors on heart outcomes.
How reliable?
Consult publication.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09977APA
Aristizábal-Colorado, David; Corredor-Rengifo, David; Sierra-Castillo, Santiago; López-Corredor, Carolina; Vernaza-Trujillo, David-Alexander; Weir-Restrepo, Danilo; Izquierdo-Condoy, Juan S; Ortiz-Prado, Esteban; Rico-Fontalvo, Jorge; Gómez-Mesa, Juan-Esteban; Abreu-Lomba, Alin; Rivera-Martínez, Wilfredo-Antonio. (2025). A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.. Frontiers in endocrinology, 16, 1605746. https://doi.org/10.3389/fendo.2025.1605746
MLA
Aristizábal-Colorado, David, et al. "A decade of progress in type 2 diabetes and cardiovascular disease: advances in SGLT2 inhibitors and GLP-1 receptor agonists - a comprehensive review.." Frontiers in endocrinology, 2025. https://doi.org/10.3389/fendo.2025.1605746
RethinkPeptides
RethinkPeptides Research Database. "A decade of progress in type 2 diabetes and cardiovascular d..." RPEP-09977. Retrieved from https://rethinkpeptides.com/research/aristizabal-colorado-2025-a-decade-of-progress
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.